ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

AVASTIN
Bladder, kidney, and other urologic cancers
CNS cancers
Colorectal and other GI cancers
Respiratory and thoracic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

AVASTIN Rx

Generic Name and Formulations:
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.

Company:
Genentech, Inc.



Therapeutic Use:

Indications for AVASTIN:

Metastatic renal cell carcinoma (mRCC) in combination with interferon alfa.

Adult Dose for AVASTIN:

Give by IV infusion after chemotherapy. Infuse 1st dose over 90 mins; if tolerated, infuse 2nd dose over 60 mins, and subsequent doses over 30 mins. 10mg/kg every 2 weeks with interferon alfa.

Children's Dose for AVASTIN:

Not established.

Pharmacological Class:

Angiogenesis inhibitor.

Warnings/Precautions:

Do not start therapy before or for at least 28 days after surgery; allow surgical incisions to completely heal (see full labeling). History of hemoptysis of ≥ ½-teaspoon of red blood: do not administer. Discontinue if GI perforation, wound healing complications, serious hemorrhage, severe arterial thromboembolic events, hypertensive crisis, nephrotic syndrome, non-GI fistula formation, or reversible posterior leukoencephalopathy syndrome occurs; suspend therapy if severe hypertension, moderate to severe proteinuria, or severe infusion reaction occurs. Cardiovascular disease. Diabetes. Renal or hepatic impairment. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis. Elderly. Increases risk of ovarian failure; inform females of reproductive potential prior to starting therapy. Pregnancy (Cat.C). Nursing mothers: not recommended.

Adverse Reactions:

Epistaxis, headache, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation, wound dehiscence/impaired healing, necrotizing fasciitis (discontinue if occurs), hemorrhage, non-GI fistula formation, arterial thromboembolic events, hypertensive crisis, reversible posterior leukoencephalopathy syndrome, infusion reactions, ovarian failure.

Generic Availability:

NO

How Supplied:

Single-use vial—1

AVASTIN

  • 16ml of 400mg/16ml vials (Qty:2)
  • appx. price $5617.00
GoodRx

Indications for AVASTIN:

Glioblastoma, as a single agent for patients with progressive disease following prior therapy.

Adult Dose for AVASTIN:

Give by IV infusion after chemotherapy. Infuse 1st dose over 90 mins; if tolerated, infuse 2nd dose over 60 mins, and subsequent doses over 30 mins. 10mg/kg every 2 weeks.

Children's Dose for AVASTIN:

Not established.

Pharmacological Class:

Angiogenesis inhibitor.

Warnings/Precautions:

Do not start therapy before or for at least 28 days after surgery; allow surgical incisions to completely heal (see full labeling). History of hemoptysis of ≥ ½-teaspoon of red blood: do not administer. Discontinue if GI perforation, wound healing complications, serious hemorrhage, severe arterial thromboembolic events, hypertensive crisis, nephrotic syndrome, non-GI fistula formation, or reversible posterior leukoencephalopathy syndrome occurs; suspend therapy if severe hypertension, moderate to severe proteinuria, or severe infusion reaction occurs. Cardiovascular disease. Diabetes. Renal or hepatic impairment. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis. Elderly. Increases risk of ovarian failure; inform females of reproductive potential prior to starting therapy. Pregnancy (Cat.C). Nursing mothers: not recommended.

Adverse Reactions:

Epistaxis, headache, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation, wound dehiscence/impaired healing, necrotizing fasciitis (discontinue if occurs), hemorrhage, non-GI fistula formation, arterial thromboembolic events, hypertensive crisis, reversible posterior leukoencephalopathy syndrome, infusion reactions, ovarian failure.

Generic Availability:

NO

How Supplied:

Single-use vial—1

AVASTIN

  • 16ml of 400mg/16ml vials (Qty:2)
  • appx. price $5617.00
GoodRx

Indications for AVASTIN:

Metastatic colorectal carcinoma, in combination with 5-FU-based chemotherapy for first- or second-line treatment; or in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine oxaliplatin-based therapy for second-line treatment in patients who have progressed on a first-line Avastin-containing regimen. Limitation of use: not for adjuvant treatment of colon cancer.

Adult Dose for AVASTIN:

Give by IV infusion after chemotherapy. Infuse 1st dose over 90 mins; if tolerated, infuse 2nd dose over 60 mins, and subsequent doses over 30 mins. 5mg/kg (when used with bolus-IFL) or 10mg/kg (when used with FOLFOX-4) once every 2 weeks until disease progression detected; 5mg/kg every 2 weeks or 7.5mg/kg every 3 weeks (when used with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based therapy).

Children's Dose for AVASTIN:

Not established.

Pharmacological Class:

Angiogenesis inhibitor.

Warnings/Precautions:

Do not start therapy before or for at least 28 days after surgery; allow surgical incisions to completely heal (see full labeling). History of hemoptysis of ≥ ½-teaspoon of red blood: do not administer. Discontinue if GI perforation, wound healing complications, serious hemorrhage, severe arterial thromboembolic events, hypertensive crisis, nephrotic syndrome, non-GI fistula formation, or reversible posterior leukoencephalopathy syndrome occurs; suspend therapy if severe hypertension, moderate to severe proteinuria, or severe infusion reaction occurs. Cardiovascular disease. Diabetes. Renal or hepatic impairment. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis. Elderly. Increases risk of ovarian failure; inform females of reproductive potential prior to starting therapy. Pregnancy (Cat.C). Nursing mothers: not recommended.

Adverse Reactions:

Epistaxis, headache, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation, wound dehiscence/impaired healing, necrotizing fasciitis (discontinue if occurs), hemorrhage, non-GI fistula formation, arterial thromboembolic events, hypertensive crisis, reversible posterior leukoencephalopathy syndrome, infusion reactions, ovarian failure.

Generic Availability:

NO

How Supplied:

Single-use vial—1

AVASTIN

  • 16ml of 400mg/16ml vials (Qty:2)
  • appx. price $5617.00
GoodRx

Indications for AVASTIN:

First-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel.

Adult Dose for AVASTIN:

Give by IV infusion after chemotherapy. Infuse 1st dose over 90 mins; if tolerated, infuse 2nd dose over 60 mins, and subsequent doses over 30 mins. 15mg/kg once every 3 weeks with carboplatin/paclitaxel.

Children's Dose for AVASTIN:

Not established.

Pharmacological Class:

Angiogenesis inhibitor.

Warnings/Precautions:

Do not start therapy before or for at least 28 days after surgery; allow surgical incisions to completely heal (see full labeling). History of hemoptysis of ≥ ½-teaspoon of red blood: do not administer. Discontinue if GI perforation, wound healing complications, serious hemorrhage, severe arterial thromboembolic events, hypertensive crisis, nephrotic syndrome, non-GI fistula formation, or reversible posterior leukoencephalopathy syndrome occurs; suspend therapy if severe hypertension, moderate to severe proteinuria, or severe infusion reaction occurs. Cardiovascular disease. Diabetes. Renal or hepatic impairment. Monitor BP every 2–3 weeks. Monitor proteinuria by dipstick urine analysis. Elderly. Increases risk of ovarian failure; inform females of reproductive potential prior to starting therapy. Pregnancy (Cat.C). Nursing mothers: not recommended.

Adverse Reactions:

Epistaxis, headache, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis; GI perforation, wound dehiscence/impaired healing, necrotizing fasciitis (discontinue if occurs), hemorrhage, non-GI fistula formation, arterial thromboembolic events, hypertensive crisis, reversible posterior leukoencephalopathy syndrome, infusion reactions, ovarian failure.

Generic Availability:

NO

How Supplied:

Single-use vial—1

AVASTIN

  • 16ml of 400mg/16ml vials (Qty:2)
  • appx. price $5617.00
GoodRx

Sign Up for Free e-newsletters